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TnF Blockade Maintains an il-10+ 
Phenotype in human effector cD4+ 
and cD8+ T cells
Ceri A. Roberts, Lucy E. Durham, Veerle Fleskens, Hayley G. Evans† and Leonie S. Taams*
Division of Immunology, Infection and Inflammatory Disease (DIIID), Centre for Inflammation Biology and Cancer Immunology 
(CIBCI), King’s College London, London, UK
CD4+ and CD8+ effector T cell subpopulations can display regulatory potential charac-
terized by expression of the prototypically anti-inflammatory cytokine IL-10. However, 
the underlying cellular mechanisms that regulate expression of IL-10 in different T cell 
subpopulations are not yet fully elucidated. We recently showed that TNF inhibitors 
(TNFi) promote IL-10 expression in human CD4+ T cells, including IL-17+ CD4+ T cells. 
Here, we further characterized the regulation of IL-10 expression via blockade of TNF 
signaling or other cytokine/co-stimulatory pathways, in human T cell subpopulations. 
Addition of the TNFi drug adalimumab to anti-CD3-stimulated human CD4+ T cell/mono-
cyte cocultures led to increased percentages of IL-10+ cells in pro-inflammatory IL-17+, 
IFNγ+, TNFα+, GM-CSF+, and IL-4+ CD4+ T cell subpopulations. Conversely, exogenous 
TNFα strongly decreased IL-10+ cell frequencies. TNF blockade also regulated IL-10 
expression in CD4+ T cells upon antigenic stimulation. Using time course experiments in 
whole peripheral blood mononuclear cell (PBMC) cultures, we show that TNF blockade 
maintained, rather than increased, IL-10+ cell frequencies in both CD4+ and CD8+ T cells 
following in vitro stimulation in a dose- and time-dependent manner. Blockade of IL-17, 
IFNγ, IL-6R, or CD80/CD86-mediated co-stimulation did not significantly regulate IL-10 
expression within CD4+ or CD8+ T cell subpopulations. We show that TNF blockade acts 
directly on effector CD4+ T cells, in the absence of monocytes or CD4+ CD25highCD127low 
regulatory T cells and independently of IL-27, resulting in higher IL-10+ frequencies after 
3  days in culture. IL-10/IL-10R blockade reduced the frequency of IL-10-expressing 
cells both in the presence and absence of TNF blockade. Addition of recombinant IL-10 
alone was insufficient to drive an increase in IL-10+ CD4+ T cell frequencies in 3-day 
CD4+ T cell/monocyte cocultures, but resulted in increased IL-10 expression at later time 
points in whole PBMC cultures. Together, these data provide additional insights into the 
regulation of IL-10 expression in human T cells by TNF blockade. The maintenance of 
an IL-10+ phenotype across a broad range of effector T cell subsets may represent an 
underappreciated mechanism of action underlying this widely used therapeutic strategy.
Keywords: tumor necrosis factor, anti-TnF, TnF inhibitors, adalimumab, interleukin-10, cD4+ T cell polarization, 
cD8+ T cell polarization, il-10 regulation
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inTrODUcTiOn
The treatment of immune-mediated inflammatory diseases 
has improved considerably over the last 20  years with the 
advent of biological therapeutics. TNFα was the first cytokine 
to be fully validated as a therapeutic target in RA (1). TNFα 
inhibitors (TNFi) have revolutionized treatment of RA 
and have been used in over a million patients worldwide 
(2). Despite the good clinical response observed in many 
patients, TNFα blockade does not offer a curative treatment; 
approximately one-third of patients do not respond and loss of 
efficacy is frequently observed (3). Importantly, it is currently 
not possible to predict which patients will respond to TNFi 
therapy. In addition, in some inflammatory diseases such as 
Sjögren’s syndrome (4, 5) and multiple sclerosis (6), TNFi have 
not shown clinical efficacy. Furthermore, and paradoxically, 
some patients treated with TNFi develop de novo autoimmune 
diseases (7). These observations indicate that the underlying 
mechanisms relating to TNF blockade in humans are incom-
pletely understood and require further exploration. The 
effects of TNFi are more wide-ranging than simply neutral-
izing the biological activity of soluble and membrane-bound 
TNFα (mTNFα). For example, by binding mTNFα, anti-TNF 
mAbs can mediate cell death by complement-dependent cyto-
toxicity and antibody-dependent cellular cytotoxicity (8–11). 
TNFα inhibitors have also been shown to affect downstream 
cytokine pathways (IL-1, IL-6, and IL-8) (2), modulate APC 
function (12), and promote regulatory T cell (Treg) expansion 
(13–15) although opposite findings regarding the latter have 
been reported (16–19).
Recent data from our laboratory demonstrated that TNF 
blockade promotes IL-10 expression in human CD4+ T cells 
(20). It was shown both cross-sectionally and longitudinally 
that inflammatory arthritis patients on TNFi therapy have an 
increased frequency of peripheral blood (PB) IL-10+ CD4+ 
T cells. These in  vivo findings were reproduced in  vitro by 
coculturing CD4+ T cells from healthy donors with autologous 
CD14+ monocytes and anti-CD3 mAb, in the presence of 
different TNFi drugs (adalimumab, infliximab, etanercept, or 
certolizumab) (20). Furthermore, we showed an increase in 
the percentage of IL-10 co-expressing IL-17+ CD4+ T cells, 
suggesting that otherwise pro-inflammatory cells displayed 
anti-inflammatory potential. Indeed, re-sorted TNFi-exposed 
IL-17+ CD4+ T cells secreted increased levels of IL-10, which 
was biologically active and could modulate markers of mono-
cyte activation (20).
Although IL-17+ CD4+ T cells are recognized as an impor-
tant cell population in inflammatory disease, other CD4+ T 
cell subsets also contribute to inflammation (21–24), as well 
as CD8+ T cells which can also be potent producers of pro-
inflammatory cytokines (25–29). In this study, we therefore 
investigated in  vitro whether TNF blockade regulates IL-10 
expression in other pro-inflammatory cytokine-producing 
T cell subsets, whether blockade of other cytokines or T cell 
activation pathways also drives IL-10 expression, and how 
TNF blockade may manifest its IL-10-regulating effect on 
T cells.
MaTerials anD MeThODs
cell isolation
Peripheral blood samples were obtained from healthy adult 
volunteers. Peripheral blood mononuclear cells (PBMCs) were 
isolated by density gradient centrifugation using Lymphoprep™ 
(Axis-Shield, Oslo, Norway). CD14+ monocytes and CD4+ T 
cells were isolated by magnetic-activated cell sorting (MACS) 
according to the manufacturer’s instructions (Miltenyi Biotec, 
Bergisch-Gladbach, Germany), and purity was confirmed by 
flow cytometry. Monocytes (average purity 98%) were isolated 
by positive selection using anti-CD14 microbeads. CD4+ T cells 
were isolated via negative depletion (average purity 95%), and 
in some experiments, CD45RO+ CD4+ T cells were subsequently 
enriched by positive selection using CD45RO microbeads (aver-
age purity 87%). In some experiments, CD4+ T cells were sorted 
to very high purity (> 99%) and part of the cells depleted of CD4+ 
CD25highCD127low Tregs by FACS-sorting after labeling cells with 
CD4 PerCP Cy5.5 (SK3), CD25 PE (M-A251), CD127 Alexa Fluor 
488 (A019D5) mAbs (all from BioLegend, Cambridge, UK). The 
study was approved by the Bromley Research Ethics Committee 
(06/Q0705/20), and written informed consent was obtained from 
all participants.
cell culture
Cells were cultured at 37°C with 5% CO2 in culture medium [RPMI 
1640 medium supplemented with 10% heat-inactivated fetal 
bovine serum (lot# 07F7435K, South American origin)] and 1% 
penicillin, streptomycin, and l-glutamine (all Life Technologies, 
Carlsbad, CA, USA). Freshly isolated bulk CD4+ or memory 
(CD45RO+)-enriched T cells (0.5 × 106) and CD14+ monocytes 
(0.5  ×  106 unless otherwise indicated) were cocultured with 
100 ng/ml anti-CD3 mAb (clone OKT3, Janssen-Cilag Ltd., High 
Wycombe, UK). Cocultures were incubated at 37°C with 5% CO2 
for 3  days. In some experiments, MACS-isolated CD4+ T cells 
were cultured alone with anti-CD3/CD28 stimulation. Anti-CD3 
(OKT3) was coated onto culture plates at 1.25 µg/ml in PBS for a 
minimum of 2 h at 37°C. Wells were then washed three times with 
PBS before adding CD4+ T cells in culture medium. Anti-CD28 
(clone CD8.2; BD Biosciences) was added to the well at a final 
concentration of 1 µg/ml. In some experiments, whole PBMCs 
were cultured with 100 ng/ml anti-CD3 mAb for up to 5 days. 
Where indicated, the following recombinant cytokines, neutral-
izing antibodies, or other reagents (from R&D Systems unless 
otherwise indicated) were added at the start of the culture period: 
recombinant human (rh) TNFα (10 ng/ml; Biosource, Camarillo, 
CA, USA), rhIL-27 (10–100 ng/ml), rhIL-10 (10 ng/ml; rhIL-10 
used to generate data in Figure S5 in Supplementary Material 
from PeproTech, Rocky Hill, NJ, USA), neutralizing/blocking 
antibodies to IFNγ (clone 25718, 10 µg/ml), IL-17 (clone 41809, 
10  µg/ml), IL-1R1 (polyclonal, 2  µg/ml), IL-10 (clone 23738, 
10 µg/ml), IL-10R (clone 8516, 10 µg/ml), and IL-27 (polyclonal, 
5  µg/ml). The following isotype control antibodies were used 
at an assay-appropriate concentration: human IgG1 (Abcam, 
Cambridge, UK), mouse IgG1, mouse IgG2a, mouse IgG2b, goat 
IgG (all R&D Systems). Clinical grade biologics were purchased 
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via Guy’s Hospital Pharmacy. Adalimumab (Abbott Laboratories, 
Chicago, IL, USA) was frozen in aliquots at −20°C and used at 
final concentration of 1 µg/ml unless otherwise indicated, tocili-
zumab (Roche, Welwyn Garden City, UK) was used at 50 µg/ml, 
and abatacept (Bristol-Myers Squibb, New York, NY, USA) was 
used at 5  µg/ml. Pediacel [Diphtheria, tetanus, pertussis (acel-
lular, component), poliomyelitis (inactivated), and Haemophilus 
type b conjugate vaccine] and Revaxis [Diphtheria, tetanus and 
poliomyelitis (inactivated) vaccine] (gifts of James Reading, Tim 
Tree lab, King’s College London) were added at a 1:1,000 dilution.
Flow cytometry
To assess intracellular cytokine expression after cell culture, cells 
were restimulated for 3 h in the presence of phorbol 12-myristate 
13-acetate (PMA; 50  ng/ml, Sigma-Aldrich), ionomycin 
(750  ng/ml, Sigma-Aldrich), and GolgiStop (according to the 
manufacturer’s instructions; BD Biosciences). In some experi-
ments, cells were labeled with a fixable viability dye (eFluor506 
or eFluor780, eBioscience, San Diego, CA, USA; LIVE/DEAD 
fixable dead cell stains, ThermoFisher Scientific) according to 
manufacturer’s instructions. Cells from cocultures were surface 
stained using anti-CD14 APC-Cy7 (HCD14; BioLegend) or 
anti-CD14 APC Vio770 (TUK4; Miltenyi Biotec) and in some 
experiments, anti-CD8 Pacific Blue (RPA-T8), before fixing in 
2% paraformaldehyde (Merck & Co., Inc., Kenilworth, NJ, USA). 
Cells were washed and then permeabilized with 0.5% saponin 
(Sigma-Aldrich) and intracellularly stained with various com-
binations of the following fluorescently conjugated antibodies 
(all from BioLegend): anti-CD3 PE Cy7 (UCHT1), anti-CD4 
PerCP Cy5.5 or Pacific Blue (both SK3), anti-IL-10 Alexa Fluor 
488 (JES3-9D7), anti-IL-17 PE (BL168), anti-IFNγ PerCP Cy5.5, 
Pacific Blue or APC (all 4  S.B3), anti-TNFα APC (MAb11), 
GM-CSF APC (BVD2-21C11). Antibodies to detect CD4 and/
or CD3 were added intracellularly, to allow for staining of these 
markers following our T cell culture conditions. Stained cells were 
acquired using a FACSCantoII or LSRFortessa (BD Biosciences); 
in most experiments, 100,000 T cell events were recorded. The 
gating strategies used to analyze intracellular cytokine expres-
sion in CD4+ T cells are described in Figure S1 in Supplementary 
Material. All flow cytometry data were analyzed using FlowJo 
software (version 7.6.1 or 10, Tree Star, Inc., Ashland, OR, USA).
enzyme-linked immunosorbent assay 
(elisa)
IL-10 was measured in cell culture supernatants using the IL-10 
ELISA MAX kit (BioLegend), according to manufacturer’s 
instructions. IL-27 was measured in cell culture supernatants 
using the DuoSet Human IL-27 ELISA (eBioscience), accord-
ing to manufacturer’s instructions. Microwell absorbance was 
read at 450 nm using a Wallac 1420 microplate reader (Perkin 
Elmer, Waltham, MA, USA). Concentrations of the analytes were 
determined based on the standard curve included on each plate.
statistical analysis
Statistical testing was performed with GraphPad Prism 5.0 or 
6.0 (GraphPad, San Diego, CA, USA). Data sets were tested for 
normality using the D’Agostino and Pearson omnibus normality 
test, followed by statistical significance testing using the appropri-
ate tests as indicated in figure legends. Data sets with n values <8 
were tested non-parametrically. P values < 0.05 were considered 
statistically significant.
resUlTs
TnF Blockade regulates il-10 expression 
in human cD4+ and cD8+ T cells
To investigate whether TNF blockade regulates IL-10 expres-
sion in different pro-inflammatory cytokine-producing CD4+ 
T cells, we isolated CD4+ T cells from PB of healthy donors 
and cocultured the cells with CD14+ monocytes and anti-CD3 
mAb (100  ng/ml) in the absence or presence of the anti-TNF 
mAb adalimumab (1 µg/ml), as previously described (20). After 
3 days, cells were restimulated with PMA and ionomycin in the 
presence of GolgiStop for 3 h and stained for cytokine expression 
(gating strategy shown in Figure S1 in Supplementary Material). 
In agreement with our previous data (20), TNF blockade led to 
a significant increase in IL-10+ cells within total CD4+ T cells as 
well as in the IL-17+ CD4+ T cell subset. In addition, we found a 
strong increase in IL-10-expressing cells within IFNγ+, TNFα+, 
GM-CSF+, and IL-4+ CD4+ T cell populations (Figures 1A,B). 
TNF blockade did not alter the frequencies of IFNγ+, TNFα+, 
or GM-CSF+ CD4+ T cell populations but did induce a modest 
increase in IL-17+ CD4+ T cells, as previously shown (20), and in 
most donors in IL-4+ frequencies, although this did not reach sta-
tistical significance (Figures S2A, B in Supplementary Material). 
Addition of an isotype control human IgG1 mAb did not promote 
IL-10 expression in CD4+ T cells (Figure S3 in Supplementary 
Material).
Contrary to the effects of TNF blockade, addition of rhTNFα 
to cocultures of CD4+ CD45RO+ T cells, monocytes and anti-CD3 
mAb led to a striking decrease in the percentage of IL-10+ cells 
within total CD4+ T cells and within IL-17+, IFNγ+, and TNFα+ 
CD4+ T cell subsets (GM-CSF+ and IL-4+ CD4+ T cells were not 
tested) (Figure  1C). TNFα addition did not significantly alter 
the frequencies of IL-17+, IFNγ+, or TNFα+ CD4+ T cell subsets 
(Figure S2C in Supplementary Material).
Since pro-inflammatory cytokine-expressing CD8+ T cells 
also contribute to immune-mediated inflammatory diseases 
(27–29), we investigated whether TNF blockade can regulate 
IL-10 expression in CD8+ T cells. We adapted the culture system 
to stimulate whole PBMC with anti-CD3 mAb (100  ng/ml) in 
the absence or presence of a dose range of adalimumab (0.01– 
10  µg/ml). After 3  days, the cultures were restimulated with 
PMA/ionomycin in the presence of Golgistop and cytokine 
expression was assessed within either the CD4+ or the CD8+ 
T cell populations. Significant increases in the percentages of 
IL-10+ cells within both CD4+ and CD8+ T cell populations were 
observed, including in the IL-17+ and IFNγ+ subpopulations 
(Figure 2). The regulation of IL-10 expression by TNF blockade 
was dose responsive in both CD4+ and CD8+ T cell subsets, with 
significantly increased IL-10+ frequencies following culture with 
either 1 or 5 µg/ml adalimumab (Figure 2C). These doses reflect 
FigUre 1 | TnF blockade promotes, while TnFα impairs il-10 expression in pro-inflammatory cD4+ T cell subsets. CD4+ T cells (open symbols) or 
CD4+ CD45RO+ T cells (filled symbols) were cocultured with autologous CD14+ monocytes and anti-CD3 mAb (100 ng/ml) in the absence or presence of the 
anti-TNF mAb adalimumab (1 µg/ml) (a,B) or rhTNFα (10 ng/ml) (c). After 3 days, cells were restimulated and assessed for intracellular cytokine expression as 
described in the methods. CD4+ T cells were gated as described in Figure S1 in Supplementary Material. (a,B) Representative dot plots (a) and cumulative data  
(B) showing the percentages of IL-10+ cells within total CD4+ T cells (n = 35), or within IL-17+ CD4+ (n = 35), IFNγ+ CD4+ (n = 24), TNFα+ CD4+ (n = 27), GM-CSF+ 
CD4+ (n = 12), or IL-4+ CD4+ (n = 8) cells after culture in the absence or presence of anti-TNF. Data were analyzed using Wilcoxon matched-pairs signed rank test. 
(c) Cumulative data showing the percentages of IL-10+ cells within total CD4+ CD45RO+ T cells or within IL-17+ (n = 8), IFNγ+ (n = 8), or TNFα+ (n = 8) CD4+ 
CD45RO+ T cells after culture in the absence or presence of rhTNFα. Data were analyzed using paired t test. Each connecting line represents an individual donor 
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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FigUre 2 | TnF blockade regulates il-10 expression in cD4+ and cD8+ T cells in a dose-dependent manner. (a,B) Freshly isolated peripheral blood 
mononuclear cells were cultured with anti-CD3 mAb (100 ng/ml) in the absence (control) or presence (anti-TNF) of adalimumab (1 µg/ml). After 3 days, cells were 
restimulated and assessed for intracellular cytokine expression as described in the methods. Cells were gated on live single CD3+ cells and IL-10 expression was 
assessed within CD4+ (a) or CD8+ (B) T cell subsets. Representative dot plots show the percentages of IL-10+ cells within total CD4+ or CD8+ T cells, or within 
IL-17+ or IFNγ+ subsets after culture in the absence or presence of anti-TNF. (c) Cells were cultured as described above in the presence of increasing doses of 
adalimumab (0–10 μg/ml). Box-whisker plots represent data from n = 6 individual donors; whiskers show minimum to maximum values. Data were analyzed by 
Friedman test with comparison to control by Dunn’s multiple comparisons test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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the clinically effective trough levels for adalimumab in human 
serum following treatment (30, 31). In agreement with data 
from the CD4+ T cell/monocyte cocultures, addition of rhTNFα 
(100 ng/ml) to anti-CD3-stimulated PBMC led to a reduction in 
IL-10+ cell frequencies, in both CD4+ and CD8+ T cells (n = 3, 
data not shown).
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Since these in vitro studies of T cell responses to TNF block-
ade all relied on monoclonal anti-CD3 stimulation, we tested 
whether TNF blockade could still elicit increased IL-10+ T 
cell responses in the context of a more physiological antigenic 
stimulation. Pediacel is a pentavalent vaccine consisting of puri-
fied diphtheria toxoid, purified tetanus toxoid, acellular pertussis 
vaccine, inactivated poliovirus, and Haemophilus influenzae type 
b polysaccharide. Revaxis is a booster vaccine containing purified 
diphtheria and tetanus toxoids and inactivated poliovirus. Each 
vaccine was added to CD4+ T cell/monocyte cocultures (1:1,000 
dilution) in the presence or absence of TNF blockade. After 
6 days, antigen-stimulated CD4+ T cells cultured in the presence 
of adalimumab demonstrated elevated IL-10+ frequencies as 
compared to cells that were not exposed to TNF blockade (Figure 
S4 in Supplementary Material).
Together these data demonstrate that in vitro TNF blockade 
provided at a physiological concentration and in a physiological 
setup can promote IL-10 expression in CD4+ and CD8+ T cells, 
including in subsets expressing pro-inflammatory cytokines.
TnF Blockade Maintains il-10 expression 
in cD4+ and cD8+ T cells
Thus far, assessment of cytokine expression following in vitro 
TNF blockade was carried out after 3  days of culture. Time 
course experiments were performed to assess the kinetics 
of IL-10 expression in CD4+ and CD8+ T cells. PBMC were 
cultured with anti-CD3 mAb in the absence or presence of 
adalimumab, and the frequencies of IL-10 expressing cells 
were analyzed 4–120  h after stimulation. The data show that 
early after TCR stimulation (18–24 h) the frequencies of IL-10 
expressing cells within CD4+ and CD8+ T cells increased rapidly 
irrespective of the presence of TNF blockade. However, at later 
time points (from 42 to 120  h), higher frequencies of IL-10+ 
cells were sustained within CD4+ and CD8+ T cells in the pres-
ence of TNF blockade (Figure  3). These experiments suggest 
that TNF blockade maintains, rather than directly induces, an 
IL-10+ phenotype in CD4+ and CD8+ T cells following TCR 
stimulation.
Blockade of TnFα, But not il-17, iFnγ, 
il-6r, or cD80/cD86-Mediated co-
stimulation, regulates il-10 in human 
cD4+ T cells
Our previous work demonstrated that in addition to adalimumab, 
other TNFα inhibitors (etanercept, infliximab, or certolizumab) 
as well as TNFR1/2 blocking mAbs were capable of increasing 
frequencies of IL-10-expressing IL-17+ CD4+ T cells (20). We 
investigated whether blockade of additional pro-inflammatory 
pathways could promote IL-10 expression in CD4+ T cells. 
Blockade of IL-17A did not enhance the frequencies of IL-10+ 
cells in any of the CD4+ T cell populations tested (Figure 4A). 
Blockade of IFNγ did not affect the percentage of IL-10+ cells 
within total CD4+ T cells, or within IFNγ or TNFα+ sub-
populations, but led to modestly increased frequencies of IL-10+ 
expressing cells within the IL-17+ population, although this effect 
was much weaker than the effect of TNF blockade in parallel 
cultures (Figure 4A). Addition of tocilizumab (IL-6R blockade) 
or abatacept (CTLA4-Ig, which blocks CD80/CD86-mediated 
co-stimulation), both of which are biologic drugs routinely used 
in the clinic to treat rheumatoid arthritis, did not increase IL-10+ 
frequencies in CD4+ T cells, IL-17+, IFNγ+, or TNFα+ CD4+ T 
cell subpopulations (Figure 4B). To determine whether blockade 
of these pathways might regulate IL-10 expression with differ-
ent kinetics to TNF blockade, IL-10+ frequencies were analyzed 
within both CD4+ and CD8+ T cells at different time points in 
anti-CD3-stimulated PBMC cultures exposed to these antibod-
ies or drugs. IL-10+ CD4+ and IL-10+ CD8+ T cell frequencies 
were not regulated at any time point by blockade of IL-17, 
IFNγ, IL-6R, or CD80/CD86-mediated co-stimulation (Figure 
S5 in Supplementary Material). Blockade of IL-1R1 in CD4+ T 
cell/monocyte cocultures resulted in a significantly increased 
proportion of IL-10+ cells within total CD4+ T cells and within 
IL-17+, IFNγ+, or TNFα+ subpopulations (Figure 4B). However, 
this effect was not replicated in either CD4+ or CD8+ T cells in 
whole PBMC cultures (Figure S5 in Supplementary Material), 
indicating that the capacity of IL-1 blockade to regulate IL-10 
expression may be dependent on the in vitro culture conditions. 
Together these data indicate that IL-10 expression in CD4+ T cells 
and CD8+ T cells can be regulated by blocking TNFα signaling, 
but not by blocking IFNγ, IL-17, IL-6R, or CD80/CD86-mediated 
co-stimulation, at least in vitro.
TnFα Blockade Directly regulates il-10 
expression in effector cD4+ T cells in the 
absence of Monocytes
Since CD14+ monocytes are major producers of TNFα, we 
explored whether the presence of monocytes was required for the 
effects of TNF blockade on regulating IL-10. CD4+ T cells were 
sorted to a very high purity (>99%) and stimulated with plate-
bound anti-CD3 and soluble anti-CD28 mAb in the absence of 
monocytes or placed in coculture with monocytes and anti-CD3 
mAb, with or without addition of anti-TNF mAb. In the CD4+ 
T cell only cultures, TNF blockade still brought about increased 
IL-10+ cell frequencies within the total CD4+ population and also 
within IL-17+, IFNγ+, or TNFα+ subpopulations, similar to the 
increased IL-10+ frequencies observed in CD4 T cell/monocyte 
cocultures (Figures 5A,B). Analysis of supernatants from anti-
CD3/CD28-stimulated CD4+ T cells by ELISA confirmed that 
levels of secreted IL-10 were increased during culture in the 
presence of TNF blockade (Figure 5C).
One potential interpretation of the observed increased fre-
quencies of IL-10+ cells following TNF blockade could be that 
there is an expansion of a pre-existing population of Tregs. Our 
previous work indicated that in three donors, MACS-depletion 
of CD4+ CD25+ cells did not impair the anti-TNF-mediated 
increase in IL-10+ frequencies within IL-17+ CD4+ T cells and 
that no increase in FOXP3+ cell frequencies was apparent upon 
TNF blockade (20). To investigate this further, MACS-isolated 
CD4+ T cells were FACS sorted to very high purity (>99%) to 
yield either total CD4+ T cells or effector CD4+ CD25-CD127+ 
T cells (Teff; depleted of CD25high CD127low Treg). These cells 
were then cultured with anti-CD3/CD28 mAbs in the absence 
FigUre 3 | Kinetics of il-10 regulation by TnF blockade. Peripheral blood mononuclear cells were cultured in the presence of anti-CD3 mAb (100 ng/ml), with 
or without anti-TNF (adalimumab, 1 μg/ml). At various time points (0–120 h), cells were restimulated and assessed for intracellular cytokine expression as described 
in the methods. (a) Representative dot plots show frequencies of IL-10+ cells within the total CD4+ T cell population 18, 42, 66, and 114 h after culture with or 
without anti-TNF. (B) Representative time course data demonstrating IL-10+ frequencies within CD4+ and CD8+ T cells in the presence (red lines) or absence (blue 
lines) of anti-TNF. (c) Box-whisker plots represent data from n = 15 individual donors showing the effect of TNF blockade on IL-10+ frequencies at 18–24 h, 
42–48 h, and 66–72 h and n = 10 individual donors at 114–20 h; whiskers show minimum to maximum values. Each time point was analyzed by Wilcoxon 
matched-pairs signed rank test. ns p > 0.05, **p < 0.01, ****p < 0.0001.
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of monocytes, or placed in coculture with monocytes and anti-
CD3 mAb, in the absence or presence of adalimumab. Our data 
show that TNF blockade still resulted in increased frequencies of 
IL-10-expressing cells in effector T cells in the absence of CD25high 
CD127low Tregs (Figure 6). Together these data indicate that TNF 
blockade regulates IL-10 expression directly in CD4+ effector 
T cells and does not require the presence of CD14+ monocytes or 
CD4+ CD25highCD127low Tregs.
FigUre 4 | Blockade of TnFα signaling, but not il-17, iFnγ, il-6r, or cD80/cD86-mediated co-stimulation, regulates il-10 in human cD4+ T cells. 
(a) CD4+ T cells (n = 6) or CD45RO+ enriched CD4+ T cells (n = 2) were cocultured 1:1 with autologous monocytes in the presence of anti-CD3 (100 ng/ml), without 
(control) or with anti-TNF mAb (adalimumab, 1 μg/ml) or neutralizing antibodies to IFNγ or IL-17 (10 μg/ml) or the appropriate isotype control antibodies (mIgG2a and 
mIgG2b, respectively). (B) CD45RO+ enriched CD4+ T cells (n = 9) were cocultured 1:1 with autologous monocytes in the presence of anti-CD3 (100 ng/ml), without 
(control) or with anti-TNF mAb (adalimumab, 1 μg/ml), tocilizumab (50 µg/ml), abatacept (5 µg/ml) or anti-IL-1R1-blocking Ab (2 μg/ml). (a,B) After 3 days, cells 
were restimulated and assessed for intracellular cytokine expression as described in the methods. Data show frequencies of IL-10+ cells within the total CD4+ T cell 
population or within IL-17+, IFNγ+, or TNFα+ CD4+ T cell subpopulations. Data were analyzed by Wilcoxon matched-pairs signed rank test with comparison to the 
appropriate control condition (ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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In support of our findings that TNF blockade can exert its 
effects on CD4+ T cells in the absence of monocytes, we did not find 
evidence for a role of the monocyte-derived anti-inflammatory 
mediator IL-27 (32) in mediating IL-10 expression in the context 
of TNF blockade. This was demonstrated by the findings that TNF 
blockade did not induce IL-27 secretion, rhIL-27 enhanced IL-10 
secretion but did not result in increased percentages of IL-10+ 
CD4+ T cells, and IL-27 blockade did not impair the increased 
IL-10+ CD4+ T cell frequencies brought about by TNF blockade 
(Figure S6 in Supplementary Material).
il-10 Partly contributes to TnF Blockade-
Mediated il-10 regulation
Finally, we explored whether modulation of IL-10 expression in 
CD4+ T cells by TNF blockade was dependent on IL-10 signaling 
itself. Neutralizing antibodies against IL-10 and IL-10R were 
added to CD4+ T cell/monocyte cocultures stimulated with 
anti-CD3 mAb, in the presence or absence of TNF blockade, 
and intracellular cytokine expression was assessed after 3 days. 
Blockade of IL-10 signaling in the absence of adalimumab led 
to significantly reduced IL-10+ frequencies within total CD4+ 
T cells and within IL-17+, IFNγ, or TNFα+ subpopulations 
(Figure  7A). When adalimumab and IL-10/IL-10R blocking 
mAbs were added in combination to the cocultures, a decrease 
in IL-10+ CD4+ T cell frequencies was observed as compared 
to the condition treated with adalimumab alone; however, an 
increase was still observed as compared to IL-10/IL-10R block-
ade alone. These data suggest that pathways additional to IL-10 
signaling could play a role in the regulation of IL-10 expression 
by TNF blockade. Indeed, when we tested whether addition of 
FigUre 5 | TnF blockade directly regulates il-10 expression in cD4+ T cells in the absence of monocytes. CD4+ T cells were stimulated with immobilized 
anti-CD3 (1.25 μg/ml) and soluble CD28 (1 μg/ml), indicated as “CD4+ T cells only,” or were cocultured 1:1 with autologous monocytes and stimulated with soluble 
anti-CD3 (100 ng/ml), indicated as “CD4+/monocyte coculture.” These cultures were carried out in the absence [(C), control] or presence [(A), adalimumab] of 
anti-TNF mAb (1 μg/ml). (a,B) After 3 days, cells were restimulated and assessed for intracellular cytokine expression as described in the methods.  
(a) Representative dot plots show frequencies of IL-10+ cells within the total CD4+ T cell population in CD4+ T cells only or CD4+/monocyte coculture, with or 
without anti-TNF. (B) Cumulative data (n = 6) showing frequencies of IL-10+ cells within the total CD4+ T cell population or within IL-17+, IFNγ+ or TNFα+ CD4+ T cell 
subpopulations. (c) After 3 days in culture but prior to re-stimulation, supernatants were harvested from CD4+ T cell only cultures (n = 15) and analyzed by 
enzyme-linked immunosorbent assay for IL-10 secretion. Data were analyzed by Wilcoxon matched-pairs signed rank test (*p < 0.05, ****p < 0.0001).
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exogenous IL-10 (10  ng/ml) could drive IL-10 expression in 
CD4+ T cell/monocyte cocultures, we found that this by itself 
was not sufficient to increase IL-10+ cell frequencies in total 
CD4+ T cells, or within IL-17+, IFNγ+, or TNFα+ subpopulations. 
Addition of rhIL-10 even decreased the percentage of IL-10+ 
cells in total CD4+ T cells and TNFα+ CD4+ T cells (Figure 7B). 
The biological activity of the recombinant IL-10 was validated 
by culturing freshly isolated monocytes with 0, 10, or 100 ng/ml 
rhIL-10 for 20 h and confirming that rhIL-10 addition resulted 
in increased CD14 and CD163 and reduced HLA-DR expres-
sion by flow cytometry, in accordance with previous studies (33, 
34) (n = 2, data not shown). We next investigated the regulation 
of IL-10 in response to rhIL-10 in both CD4+ and CD8+ T cells 
using whole PBMC cultures assessed for IL-10 expression over 
a 5-day time course (Figure S5 in Supplementary Material). 
We found that at earlier time points (18–24 h), rhIL-10 addi-
tion reduced IL-10+ CD4+ T cell frequencies (n = 6, p = 0.03, 
Wilcoxon matched-pairs signed rank test), while at later time 
points (66–72 and 114–120  h), rhIL-10 slightly increased 
IL-10+ CD4+ T cell frequencies (n =  6, p =  0.03, Wilcoxon 
matched-pairs signed rank test). IL-10+ CD8+ T cell frequencies 
remained very low throughout, regardless of rhIL-10 addition. 
Together, these data indicate that IL-10 signaling contributes in 
part to TNF blockade-mediated regulation of IL-10 expression 
in CD4+ T cells, but that other factors also play a role. The effects 
of exogenous IL-10 on regulating IL-10 expression in CD4+ 
T cells appear to be dependent on both time and in vitro culture 
conditions.
DiscUssiOn
Here, we show that T cell stimulation in the presence of TNF 
blockade maintains the proportion of cells expressing the anti-
inflammatory cytokine IL-10. This phenomenon is observed 
in total CD4+ and CD8+ T cells as well as within a variety of 
pro-inflammatory cytokine-expressing (IL-17+, IFNγ+, TNFα+, 
GM-CSF+ or IL-4+) subpopulations. TNF blockade regulates 
IL-10 expression whether CD4+ T cells are stimulated in the pres-
ence or absence of monocytes, and when an antigenic stimulus is 
used in place of monoclonal anti-CD3 stimulation. We found that 
blockade of IL-17, IFNγ, IL-6R, or CD80/CD86-mediated co-
stimulation did not regulate IL-10 expression in CD4+ or CD8+ 
FigUre 6 | TnF blockade increases il-10+ cell frequencies in cD4+ effector T cells depleted of regulatory T cells (Tregs). MACS-isolated CD4+ T cells 
from four donors were FACS-sorted to high purity (>99%) to obtain total CD4+ cells (Total) or CD4+ effector T cells depleted of CD25high CD17low Tregs (Teff). Total/
Teff CD4+ T cells were either stimulated with immobilized anti-CD3 (1.25 μg/ml) and soluble CD28 (1 μg/ml) or cocultured 1:1 with autologous monocytes and 
stimulated with soluble anti-CD3 (100 ng/ml), in the absence (control) or presence (anti-TNF) of adalimumab (1 μg/ml). After 3 days, cells were restimulated and 
assessed for intracellular cytokine expression as described in the methods. (a,B) Representative dot plots show frequencies of IL-10+ cells within the CD4+ T cell 
population in (a) anti-CD3/28-stimulated total/effector CD4+ T cells or (B) total/effector CD4+ T cell/monocyte cocultures, both with or without anti-TNF. (c,D) 
Cumulative data (n = 4) showing frequencies of IL-10+ cells within the CD4+ T cell population or within IL-17+, IFNγ+, or TNFα+ CD4+ T cell subpopulations, in either 
(c) anti-CD3/28-stimulated total/effector CD4+ T cells or (D) total/effector CD4+ T cell/monocyte cocultures, both with or without anti-TNF.
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T cell subpopulations. Blocking antibodies to IL-1R1 resulted in 
increased IL-10+ CD4+ T cell frequencies when added to CD4+ 
T cell/monocyte cocultures, but this effect was not replicated in 
whole PBMC cultures. One explanation could be that additional 
cell types are present in PBMC cultures that can produce or 
respond to IL-1. Neither CD4+ CD25highCD127low Tregs nor IL-27 
was required for TNF blockade to exert its IL-10-promoting 
effects.
Our data confirm and extend our previous work showing 
that TNF blockade promotes IL-10 expression in CD4+ T cells 
(20) and support other findings in the literature. A small study 
of RA patients found that frequencies of IL-10+ PBMC were 
increased following treatment with infliximab (14). However, 
in the three patients studied, it was not confirmed which cell 
subset(s) expressed IL-10. Ebert later showed that supernatants 
from cultures of either monocytes (adherent PBMC) or T cells 
(non-adherent, CD14− CD20− HLA-DR− PBMC), contained 
increased IL-10 following exposure to infliximab in vitro (35). 
Antiga et  al. demonstrated increased percentages of IL-10+ 
CD4+ T cells in T cell blasts isolated from skin lesions of 
psoriasis patients, following treatment with etanercept (36), 
and PB IL-10+ CD4+ T cells were also increased in posterior 
uveitis patients following treatment with a p55 TNFα receptor 
fusion protein (37). Earlier studies assessing mouse transgenic 
T cells (38) or human CD4+ T cell clones (39) also found that 
TNF blockade led to increased IL-10 production in cell culture 
supernatants. In further support of our data, Boks et al. showed 
that blockade of TNFα during in vitro priming of naïve CD4+  
FigUre 7 | il-10 expression in cD4+ T cells is inhibited by il-10 blockade, in both the absence and presence of TnF blockade. (a) CD45RO+ enriched 
CD4+ T cells were cocultured 1:1 with autologous monocytes in the presence of anti-CD3 (OKT3,100 ng/ml), with or without anti-TNF mAb (adalimumab, 1 μg/ml), 
with or without neutralizing antibodies to IL-10 and IL-10R (both 10 μg/ml). After 3 days, cells were restimulated and assessed for intracellular cytokine expression 
as described in the methods. Box-whisker plots show frequency of IL-10+ cells within the total CD4+ T cell population or within IL-17+, IFNγ+ or TNFα+ 
subpopulations; whiskers show minimum to maximum values. Data were analyzed by repeated measures ANOVA, with comparison between selected conditions by 
Sidak’s multiple comparison test (n = 9). (B) CD45RO+ enriched (filled symbols, n = 5) or bulk (open symbols, n = 1) CD4+ T cells were cocultured 1:1 with 
autologous monocytes and stimulated with anti-CD3 mAb (100 ng/ml), with or without recombinant human IL-10 (rhIL-10; 10 ng/ml). After 3 days, cells were 
restimulated and assessed for intracellular cytokine expression as described in the methods. Data show frequencies of IL-10+ cells within the total CD4+ T cell 
population or within IL-17+, IFNγ+, or TNFα+ subpopulations and were assessed by Wilcoxon matched-pairs signed rank test (ns p > 0.05, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001).
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T cells with tolerogenic DCs favored the development of IL-10+ 
CD4+ T cells (40). Thus, TNFi-mediated regulation of IL-10 in 
CD4+ T cells has been indicated by a growing number of in vitro 
and ex vivo studies.
The presence of IL-10-expressing CD8+ T cells has been 
reported in several mouse models of infection, including acute 
influenza infection (41), chronic Mycobacterium tuberculosis 
infection (42), and coronavirus-induced encephalitis (43). 
Furthermore, IL-10+ CD8+ T cells have been found in patients 
with HIV (44) and chronic hepatitis C infection (45). IL-10 
expression in CD8+ T cells can be induced by IL-4, either alone 
(46) or in combination with IL-12 (47), or dexamethasone 
(48). However, to the best of our knowledge, this is the first 
report showing that TNF blockade can regulate IL-10 expression 
in CD8+ T cells.
IL-27 can stimulate IL-10 production by various effector CD4+ 
T cell subsets (32, 49, 50). Our data suggest however that the 
capacity of TNF blockade to affect IL-10 expression in CD4+ T 
cells is not dependent on IL-27. In agreement with other work on 
human T cells (51, 52), we found that addition of recombinant 
IL-27 to anti-CD3/CD28-stimulated CD4+ T cells resulted in 
increased IL-10 secretion, although this was not strictly dose-
dependent. However, in contrast to these other studies, which 
used naïve CD4+ T cells, our analysis of intracellular cytokine 
expression did not demonstrate increased IL-10+ CD4+ T cell 
frequencies after 3  days in culture with IL-27. This is possibly 
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due to different kinetics of IL-10 expression in a bulk CD4+ T 
cell population.
It is of note that although in CD4+ T cell/monocyte cocul-
tures IL-10 blockade led to reduced IL-10+ frequencies in both 
the presence and absence of TNF blockade, IL-10 addition by 
itself was not sufficient to drive IL-10 expression in CD4+ T 
cells. These data are in line with previous work showing that 
IL-10 is necessary but not sufficient to enhance development of 
IL-10-producing Tr1 cells following in  vitro differentiation in 
the presence of vitamin D3 plus dexamethasone (53). However, 
when added to anti-CD3-stimulated whole PBMC cultures, 
rhIL-10 did slightly increase IL-10+ CD4+ T cell frequencies 
after 3 and 5 days in culture, indicating that the regulation of 
IL-10 expression in CD4+ T cells is dependent on in vitro culture 
conditions.
In inflammatory diseases, such as RA, the normal balance 
of immune regulation is disturbed and T cell-derived pro-
inflammatory mediators can contribute to disease pathogenesis 
in an uncontrolled manner. This study indicates that a potentially 
immunoregulatory IL-10+ phenotype is broadly maintained 
in effector T cells following exposure to TNF blockade, which 
may represent an underappreciated mechanism of action for 
this widely used therapeutic strategy. We previously provided 
evidence that the IL-10 secreted by IL-17+ CD4+ T cells following 
TNF blockade is biologically active (20); however, further work is 
required to investigate whether the increase in IL-10+ frequencies 
across different T cell subpopulations is functionally relevant in 
the context of inflammatory disease. Additional insights into 
the underlying molecular mechanisms via which TNF blockade 
maintains IL-10 expression could identify potential targets for 
novel therapeutic strategies.
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